Exelixis Inc.

(EXEL) Trade

By |

Profile

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer as Cometriq and advanced renal cell carcinoma, or kidney cancer, as Cabometyx. Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma. The company has partnerships with larger pharmaceutical and biotech firms to develop its pipeline, including Bristol, Sanofi, and Merck.

Contact Information

Website: www.exelixis.com
Email: shubbard@exelixis.com
Main Phone: +1 650 837-7000
Address: 210 East Grand Avenue
State: CA
City / Town: South San Francisco
Country: USA
Postal Code: 94080

Issuer Information

Exchange: NGS
CEO: Michael M. Morrissey
Employees: 372
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)
$ 21.80 $ 0.82 (3.91%)
Last Price 21.80 Change $ 0.82 Change % 3.91 Tick N/A
Bid 21.19 Bid Size 300.00 Ask 22.09 Ask Size 300.00
Open 21.36 High 22.37 Low 21.17 Prev Close 20.98
Last Trade Volume 4.5 mi 52 Wk Hi 32.20 52 Wk Low 13.42
Market Cap 6.5 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 298,983,135.00 EPS (TTM) 1.18 PE Ratio 17.40 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 35 97
Number of Buys 21 48
Number of Sells 14 49
Net Activity 67225 16693
Last 10 Buys Shares
Lance Willsey 1,000
Lance Willsey 1,000
Lance Willsey 1,000
Lance Willsey 1,000
Vincent T. Marchesi 1,000
Vincent T. Marchesi 1,000
Lance Willsey 1,000
Lance Willsey 1,000
Lance Willsey 1,000
Vincent T. Marchesi 1,000
Last 10 Sell Shares
Michael M. Morrissey 1,000
Lance Willsey 1,000
Patrick J. Haley 1,000
Vincent T. Marchesi 1,000
Charles Cohen 1,000
Patrick J. Haley 1,000
Stelios Papadopoulos 1,000
Patrick J. Haley 1,000
Jeffrey J. Hessekiel 1,000
Gisela M. Schwab 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 40 40 40 40
Low Target Price Estimate 29 29 29 29
Mean Target Price Estimate 33.83 33.83 33.83 33.83
Standard Deviation 5.12 5.12 5.12 5.12
Date of Most Recent Estimate 06/01/18 05/29/18 05/17/18 06/01/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 5 5 5 5
Moderate Buy 2 2 1 2
Hold 1 1 2 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.5 1.5 1.63 1.8